Currently Viewing:
Newsroom
Currently Reading
Dexcom Launches API to Promote Diabetes App Innovation
September 25, 2017 – Mary Caffrey
Study Finds Areas of Bone Damage in Seniors With Type 2 Diabetes
September 21, 2017 – Mary Caffrey
AADE to Work on Diabetes Prevention With Truck Drivers, Other At-Risk Groups
September 20, 2017 – Mary Caffrey
Fine-tuning Enzyme Could Help Manage Diabetes, Obesity, Cancer
September 19, 2017 – Mary Caffrey
Consumption of Salt Associated With Increased Risk of Type 2 Diabetes, Researchers Say
September 18, 2017 – Laura Joszt
Sotagliflozin Reduces A1C With Less Insulin in Type 1 Diabetes, but DKA Rates Increase
September 15, 2017 – Mary Caffrey
Sanofi: Patient-Driven Insulin Titration Better for A1C
September 14, 2017 – Mary Caffrey
A Heavier Wife Can Lead to a Husband's Diabetes, Study Finds
September 13, 2017 – Mary Caffrey
Medtronic Announces Recall of Diabetes Infusion Sets
September 12, 2017 – Mary Caffrey

Dexcom Launches API to Promote Diabetes App Innovation

Mary Caffrey
The move to give entrepreneurs access to patient-approved continuous glucose monitoring data fits with the company's prediction that insulin pumps will become a thing of the past, and most of the heavy lifting of delivery will be done by a smartphone.
Dexcom, known to people with diabetes for making continuous glucose monitoring (CGM) systems, has handed a valuable tool to developers of compatible diabetes software with the launch of a public application programming interface, or API.

Release of the API will allow third-party developers to connect with patient-authorized CGM data to create software applications, which Dexcom hopes will drive more digital solutions for payers, providers, and, most critically, people living with the disease.

“In launching this developer platform, Dexcom combines our CGM data expertise with the creativity of the developer ecosystem to enable new solutions and business models in the treatment and management of diabetes,” Annika Jimenez, Dexcom’s senior vice president of data, said in a statement. “Dexcom believes in data mobility and customer choice.”

The announcement came with an endorsement from Jeff Dachis, founder and CEO of One Drop, a digital diabetes management solution that uses Dexcom’s API. “This partnership will help drive innovation and will bring about more affordable, accessible, scalable, and effective solutions. It’s a big win for people with diabetes.”

Developers in the United States can register for the API at http://developer.dexcom.com. Companies already taking part include Tidepool, Rimidi, Evidation, Ensa, and App Practice, in addition to One Drop.

Rakesh Patel, MD, of App Practice, said in the announcement that the availability of the data would allow clinicians to make timely changes and insulin adjustments more effectively. “Access to patient data like this enables clinicians to dramatically improve patient care and can lower healthcare costs,” Patel said.

Access to patient data has shaped the race for diabetes solutions and marked several of the partnerships among tech giants, diabetes startups, or pharmaceutical companies in the past few years. There’s also been concern that alignment of payers with dominant technology companies that control large amounts of data could stifle innovation. In particular, the transaction between UnitedHealthcare and Medtronic drew ire among patients and advocacy groups in 2016.

Dexcom, meanwhile, has made it clear it does not want to be in the insulin pump business; a senior company official said recently the company foresees a future in which most of the heavy lifting of insulin delivery will be done by a patient’s smartphone.

By creating the public API, the company lowers costs for several smaller entrepreneurs and invites new ones to participate. Also, Dexcom encourages payers to connect to the platform, just as experts foresee growth in CGM among patients with type 2 diabetes (T2D). In the United States, 30 million Americans have diabetes; only about 1.25 million have type 1 diabetes, whereas the clear majority have T2D.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up